INTRODUCTION
Barrett's esophagus (BE) is a premalignant condition in which intestinal metaplasia replaces normal squamous epithelium at the distal esophagus [1, 2] . BE predisposes for esophageal adenocarcinoma (EAC), and current guidelines recommend endoscopic surveillance for early detection [1, 2] and endoscopic treatment of early esoph ageal neoplasia [37] . BE surveillance is associated with earlier stage EAC and increased survival [8, 9] . In addition, endoscopic treatment can result in complete eradication of both dysplasia and intestinal metaplasia and a reduced risk of disease progression [7, 1012] . Mortality in the overwhelming majority of BE patients is not related to EAC but is rather due to nonesophageal malignancies and cardiovascular disorders [11, 13, 14] . All cause mortality is higher in patients with advanced grades of BE dysplasia compared to matched controls [11, 14] . Non esophageal cancer mortality in Danish patients with high grade dysplasia (HGD) was higher than nondysplastic BE and matched controls, though comparing HGD to nondysplastic BE was not an endpoint, and was not analyzed for significance [14] . Another population based cohort study conducted in Israel showed increased prevalence of colorectal, prostate, kidney, bladder and thyroid cancer in BE patients occurring at a younger age compared to matched controls [15] . To the best of our knowledge, no other publications examined the potential association between histologic features of BE and non EAC cancer morbidity. Better characterization of cancer morbidity among patients with BE may identify risk factors and enable better surveillance, cancer prevention and optimal resource use [16] . Therefore, the primary aim of the current study was to study cancer morbidity and overall mortality within a prospectively followed cohort of BE patients according to grade of dysplasia.
MATERIALS AND METHODS

Patients and definitions
All consecutive BE patients undergoing upper endoscopy at the TelAviv Sourasky medical center between 20092014 were included, thus determining sample size. Clinical, endoscopic, and histologic data were collected from patient files in a prospective manner between 2009 and 2014. Prestudy data was retrospectively collected, as far back as 2004.
BE was defined as having a characteristic endoscopic appearance of any length, and histologic diagnosis of intestinal metaplasia with goblet cells on biopsies taken from the columnar esophageal mucosa [1] .
Study design
This is a retrospective cohort study.
Study setting
TelAviv Sourasky medical center a tertiary referral center for BE.
Data retrieval and databases used
Data collection included the following parameters for each endoscopy: BE segment lengthcircumferential and maximal lengths were calculated and recorded according to the Prague classification [17] . We categorized the BE segment length as long (BE segment measuring 3 cm and above), short (12.9 cm), and ultrashort (< 1 cm). Presence of endoscopic abnormalities was also recorded. Histologic results for each endoscopy were classified as no dysplasia, low grade dysplasia (LGD), HGD, intramucosal adenocarcinoma (IMC), and EAC [18] . All biopsies with suspected dysplasia were reviewed by 2 expert GIpathologists. If a patient had more than one dysplasia result or endoscopic report, the most severe dysplasia as well as the longest BE segment during follow up were chosen for analysis, respectively. Individual follow up was censored either by a diagnosis of cancer, at the end of the follow up period (December 2014), or death. Patient information collected included age, gender, cancer history (including type of cancer), individual number of endoscopies during the study period, and date of death.
The primary outcome of this study was nonBE cancer incidence, and secondary aims included BE related cancer and overall mortality. In order to determine the difference in cancer morbidity in patients with higher degrees of dysplasia, we compared patients who had HGD and patients with LGD or nondysplastic BE (non HGD group).
Cancer morbidity data was retrieved from the Israeli national cancer registry (NCR). The NCR records all incident cases of malignant neoplasms other than basal or squamous cell skin cancers. Trained registrars review available documents from hospitals, pathology labs, and death certificates from local health authorities. Upon retrieval of data from the NCR, its records were updated until December 2014.
Cancers were categorized as BE related or nonBE related. As diagnostic inaccuracies between EAC and gastric cardia adenocarcinoma are known to occur [19] , we classified them both as BE cancers. All other malignancies were recorded as nonBE cancer. For all cancer free analysis, we used cancer cases which occurred within the follow up period. We also recorded cases occurring before the first available endoscopy as pre-study cancer, and reported the total lifetime cancers retrieved from the NCR.
The date of death information was retrieved from the Central Bureau of Statistics.
This study was approved by our center's institutional review board approval number 002209. As data were collected from medical records throughout the study, informed consent was waivered by the institutional review board. For each patient, the cancer free survival time was calculated based on the first endoscopy date (i.e., start date) and the first cancer date or the end of the followup date (December 2014) for patients who were cancer free. For non-BE cancer, we used the first non-BE cancer date for the calculation. KaplanMeier curve was utilized to compare survival trends, using the Logrank test. All KaplanMeier analysis was done for patients with multiple endoscopies to avoid confounding. In addition, the Cox regression was used to perform univariate and multivariable regression in all patients (adjusting for potential confounders, found to be associated with HGD in the univariate analysis), displaying the hazard ratios (HRs) and adjusted HR (Adj.HR) with 95% confidence intervals (95%CI).
Statistical analysis
The statistical analyses were performed using SAS 9.4 software (SAS Institute Inc., Cary, NC, United States).
Significance was set at P < 0.05.
RESULTS
A total of 387 patients with biopsy proven BE were included with endoscopic data starting at May 2004 until December 2014. One foreign patient with missing NCR data was excluded, leaving 386 for analysis, see Figure 1 . The analysis for nonBE cancer among BE patients with or without dysplasia, included 379 patients who did not develop IMC or BEcancer during the study followup. The total cohort number of endoscopies was 963, with a mean of 2.5 ± 2.0 endoscopies per patient. Two hundred sixtyeight (69.4%) were males with an overall mean age of 60.0 ± 13.1 years (Table 1) . Long segment BE was found in 225 (59.7%) of patients. The worst degrees of dysplasia/neoplasia were LGD, HGD, IMC, and EAC in 19 (4.9%), 12 (3.1%), 1 (0.3%), and 6 (1.6%), respectively. Study inclusion per year is shown in Supplementary Table 1 in the supplementary section.
Seventyfive patients (19.4%) had invasive lifetime cancers, reported by the NCR database, of whom 10 (2.6%) had lifetime BE cancers. There were prestudy cancers in 50 (13%) patients, of which 3 were BE cancers (0.8%) and 47 were nonBE cancers (12.2%). Incident cancers occurred in 7 BE cancers (1.8%) patients and nonBE cancers in 18 (4.7%) patients. The prestudy cancers and incident cancers are detailed in Table 2 . Of note, one of the 2 esophageal prestudy cancers was a squamous cell carcinoma and not EAC. Subjects pre study cancers were not included in cancer outcome analysis as they occurred outside of follow up period as explained in the materials and methods section.
The HGD group included 12 patients, and the non HGD group (LGD and nondysplastic BE) 367 patients. Comparison of these 2 groups is presented in Table 2 for demographic and endoscopic characteristics. In the HGD group 2 patients (16.7%) had nonBE incident For the primary endpoint, nonBE cancer free survival was worse in patients with HGD compared with non HGD, as shown in the KaplanMeier curves, Figure 2A . Logrank test Pvalue was 0.0166 (n = 239), The 2year and 10year nonBE cancer free survival rates were 91% and 82% and 98% and 95% for the in HGD group and nonHGD group, respectively, in patients with multiple endoscopies. Univariate Cox regression analysis, Table  3 , showed that HGD was not a significant predictor non-BE cancer (HR = 3.40, 95%CI: 0.7814.84, P = 0.104), but in multivariable Cox regression adjusting for age, cancer history and number of endoscopies, HGD was significantly associated with increased risk for nonBE cancer (Adj.HR = 8.32, 95%CI: 1.3551.33, P = 0.022).
cancers (lung and pancreatic cancers), compared with 16 (4.4%) patients in the non HGD group who had 18 cancers (in patients with 2 incident cancers the earliest one was included for analysis). As expected, patients with HGD, had a higher frequency of endoscopies, higher rate of endoscopic abnormalities (P < 0.001), and a longer maximal extent of BE compared with non HGD patients (P < 0.01).
KaplanMeier survival curves for cancer free and allcause survival are presented in Figure 2 . To avoid the confounding effect of the number of endoscopies and assuring longer followup for all patients, Kaplan Meier analysis was done on patients with at least 2 endoscopies. Figure 1 Study flow-chart. 1 Out of the 386 patients, 245 (63%) had more than one endoscopy; 2 Out of the 379 patients, 239 (63%) had more than one endoscopy. BE: Barrett's esophagus; NCR: National Cancer Registry. Examining the secondary endpoints, we saw a significant difference in the any-cancer free survival time among patients with HGD and patients with nonHGD, Figure 2B . Again, the worse outcome was in the HGD group, log rank test P < 0.001 (n = 245). For allcause cancer, the 2year and 10year cancer free survival were 86% and 64% in the HGD group compared to 98% and 93% at the non HGD group, respectively.
Occurrence of allcause cancer was associated with the maximal extent of the BE segment and HGD at the univariate analysis, see Table 4 . After adjusting for age, number of endoscopies and prestudy cancer history, HGD was independently associated with allcause cancer occurrence (Adj.HR = 4.28, 95%CI: 1.1715.76, P = 0.029) whereas the maximal BE segment length was borderline significant (Adj.HR = 1.13 95%CI: 1-1.27, P = 0.050).
As BE cancer outcome was uncommon, we compared it with the Fisher exact test and not by statistical modeling. Among the 7 incident BEcancer cases, 3 (42%) had HGD previously documented, while among the other 379 BE patients, only 12 (3.2%) had HGD (RR = 18.6, 95%CI: 4.675.6, P = 0.002) There were 31 (8%) patients who died out of the entire cohort during the study period. Two (22.2%) of patients with IMC/EAC, 2 (16.7%), and 27 (7.0%) in the HGD and nonHGD groups respectively. Kaplan Meier curve for mortality presented no association between HGD and allcause mortality, Figure 2C . Log rank test P = 0.376 (n = 245). Cox regression analysis maintained this conclusion, after adjusting for age, cancer history and number of endoscopies for HGD (Adj. HR = 3.19, 95%CI: 0.6615.46, P = 0.149).
The KaplanMeier curves for cancer free survival of the total cohort, including patients with a single endoscopy are shown in the online supplementary section, Supplementary Figure 1. 
DISCUSSION
Our study reveals an association between BE with HGD and cancer outcome which, to the best of our knowledge, has not been reported before. Our main finding is that BE patients with HGD had a significantly higher risk of having nonBE cancer compared to patients with lower grades of dysplasia. This association was found in the group of patients who underwent more than a single endoscopy, which decreases the chance of dysplasia grade misclassification.
As expected, the known association between BE with HGD and adenocarcinoma of the esophagus or gastroesophageal junction was also demonstrated in this study. Since this was an uncommon event, we did not use survival analysis models to investigate the association. We did not find HGD to be associated with allcause mortality compared to lower levels of dysplasia.
The association between BE and extraesophageal cancers mortality has long been studied. Most studies established increased cancer mortality risk in BE compared to normal population, even after matching for other risk factors [14, 15, 2023] . In a large Danish registry study [14] , patients with BE had a 71% increased allcause mortality compared to matched controls, while the non esophageal cancer mortality incidence rate was increased by 77% (14.7 cases per 1000 patient years) and was the leading cause for mortality. Moreover, patients with HGD had higher nonesophageal cancer mortality rates than patients with LGD or nondysplastic BE: HR (95%CI) were 2.47 (1.983.07), 1.62 (1.312.01), and 1.44 (1.34-1.56), respectively. However, statistical significance of the difference between groups was not reported.
Wolf et al [11] looked at patients following radiofre quency ablation, in a United States based registry. A dose response effect for allcause mortality to baseline BE degree of dysplasia with HGD having an adjusted odds ratio (95%CI) of 2.7 (1.74.4) vs 1.3 (0.72.2) for
LGD and 1.6 (0.8-3.3) for indefinite dysplasia compared with nondysplastic BE. SolaymaniDodaran et al [13] showed increased cancer specific mortality rates in patients with BE, but did not stratify the population according to dysplasia grade. The above data described mortality, and not mor bidity. Due to the lack of data about nonBE cancer morbidity we aimed to correlate it with BE degree of dysplasia. Assuming patients with dysplastic BE have higher mortality rate, our findings imply that the above association may be related, at least in part, to increased cancer incidence.
The role of gastro-esophageal reflux disease in BE is clear, but what predisposes certain patients to develop BE and neoplasia is still under debate. Studies have linked various factors such as smoking [24, 25] , abdominal obesity [26, 27] genetics [28] , and nutrition [29, 30] to BE and dysplasia/EAC. Most of these factors are also associated with other nonBE malignancies [31] . The molecular basis of BE and EAC has been studied avidly, P53 and SMAD4 somatic mutations play a role in dysplastic BE and EAC development [3235] . P53 is also a key player in many nonesophageal neoplasia, such as colorectal cancer, prostate cancer, and melanoma [36] . SMAD4 somatic mutations are prevalent in pancreatic cancer and colorectal cancer [37] . This complex associ ation of molecular and environmental factors with BE dysplasia/neoplasia and other cancers may indicate similar cancer pathways induced by similar exposures.
Our findings imply that HGD in BE may be a marker of increased risk for cancer morbidity and therefore may require extraesophageal surveillance and lifestyle modification to prevent and decrease cancer risk.
As for now, it may be prudent to stringently perform routine cancer screening tests among patients with BE and those with HGD in particular, according to age and gender and to recommend adherence to cancer protective lifestyle.
Given the low incidence of EAC mortality rates in BE patients, the riskbenefit and cost effectiveness of surveillance has been a matter of discussion, with conflicting evidence concerning EAC and mortality pre vention and cost effectiveness [9, 3840] . We show another potential motivation for BE surveillance to better define overall cancer risk.
Our study carries some limitations. Investigator initiated studies done in teaching hospitals are prone to referral bias and are also smaller in size than population based studies, limiting generalizability, and perhaps overestimating associations. On the other hand, patients with dysplasia are usually managed in a tertiary center.
We could not ascertain how long patients had BE before study inclusion, which may have influenced the outcomes. However, these estimates are approximate at best, as BE itself may be asymptomatic and this limitation is shared by other studies.
In our study, we adjusted for age and a past history of cancer, but we were not able to adjust for other risk factors such as lifestyle parameters. Our study did not include a population with no BE as a control, but we assume based on previous studies [14, 15, 2023] , that cancer rates are even lower in subjects with no BE. Death as an outcome was determined in this study according to ministry of health database, but cancer specific mortality was not available and cannot be associated with cancer morbidity. Our major limitation is the low statistical power due to the small number of patients with HGD and incident cancers, which reflects real life clinical data of an uncommon condition. In addition, the majority of patients were male, as prevalent in other studies [41] . Gender may act as a confounder when addressing cancer morbidity (as with prostate and breast cancer). Again, this reflects reality in many centers treating patients with BE.
The advantages of our study include a prospective comprehensive 6 year follow up of a relatively large number of consecutive BE patients within a single referral center, enabling a uniform data collection and fully verified clinical, endoscopic and revised histologic data.
In conclusion, in our cohort we found an endoscopic and histologic profile comparable to other Western world data. NonBE related malignancies were more prevalent, and significantly associated with HGD as well as BE related malignancies in comparison with non HGD BE. Our findings suggest BE patients with HGD may have a significantly higher overall risk for cancer morbidity. This may imply endoscopic surveillance for BE patients could aid in prediction of allcause cancer risk and encourage current cancer prevention measures such as lifestyle modification and appropriate cancer screening among patients. Further characterization of cancer morbidity and mortality profile among patients with BE should follow with large populationbased studies.
ARTICLE HIGHLIGHTS
Research background
Patients with Barrett's esophagus (BE) are at risk for esophageal adenocarcinoma, and surveillance is recommended. However, non-esophageal cancer is the leading cause of death in this population. This raises questions about the focus we give to surveillance for esophageal cancer, and the need for broader cancer surveillance.
Research motivation
We wanted to better describe the non-esophageal cancer morbidity in patients with BE, and specifically in patients with high grade dysplasia (HGD). Finding that patients with HGD carry a higher non-esophageal cancer risk can direct efforts and resources for cancer prevention.
Research objectives
We aimed to describe the non-esophageal cancer morbidity in patients with BE, and to test whether patients with HGD have a higher risk as compared to low grade dysplasia. Indeed, in this study we have shown that compared to non-HGD, patients with HGD have a lower all cancer and non-BE cancer free survival. The significance of these findings is in the recognition of the importance of total cancer surveillance in these patients. In addition, by comparing non-esophageal cancer morbidity in HGD and less dysplastic BE, we show the added value of information received in surveillance endoscopies. These findings put the foundations for larger cohort studies, preferably multicenter for reaching a significant number of patients.
Research methods
Endoscopic and histologic data were collected, and cancer morbidity data were retrieved from the national cancer registry. We compared non-esophageal cancers, all cancers and mortality between patients with HGD and less dysplastic BE. Cancer free survival analysis was done.
Research results
We found patients with HGD had a worse non-BE cancer free survival and all cancer free survival. The higher frequency of non-esophageal cancer in patients with HGD raises the question as to the reason for this association. Further population based and mechanistic studies are required to further investigate these reasons.
Research conclusions
Our study shows that HGD may act as a marker for all cause cancer outcome, not just esophageal cancer. Perhaps it reflects a behavioral, environmental and genetic inclination towards malignancy. After endoscopic treatment for the dysplasia, we should focus our efforts to teach these patients about healthier lifestyle, and modifiable cancer risk factors such as smoking cessation and weight reduction. Perhaps in this population, screening for other malignancies may hold a different cost-effective profile.
Research perspectives
Patients with BE and HGD have a higher non-esophageal cancer risk, on top of esophageal cancer risk. This should be confirmed in more prospective studies and population-based studies. This may shift the focus of esophageal based surveillance to a more holistic cancer prevention program for certain patients. Future research should include larger cohorts of patients from multiple centers, with detailed endoscopic and histologic data as well as other cancer risk factors including obesity measures and lifestyle behaviors as smoking, physical activity and dietary intake to better encompass risk stratification and prevention potential.
